$ABT · ABBOTT LABORATORIES

Abbott reported Q3 2026 results with reported sales of $13.01B (+14.5% YoY) and comparable sales growth of 7.0%. GAAP diluted EPS was $0.53, weighed down by $1.56B in specified items including $670M in legal settlements and $841M in intangible amortization. Adjusted diluted EPS was $1.42, up 9.2% from $1.30 a year ago. The company tightened its full-year 2026 adjusted EPS guidance to $5.50–$5.55 and guided Q4 at $1.62–$1.67.

Extended-hours trading shows ABT at $97.93, down 4.64% from the $102.70 regular close. The GAAP EPS miss ($0.53 vs. adjusted $1.42) and $670M legal settlement charge appear to be weighing on shares despite the adjusted beat and reaffirmed guidance midpoint.

The $670M legal settlement charge cratered GAAP earnings, but underlying business momentum is strong with 7% comparable sales growth and a pipeline of new product approvals across diabetes, AFib, and

Abbott's 7.0% comparable sales growth and robust medtech pipeline (Libre Duo, TactiFlex Duo, Amulet 360) reinforce its diversified healthcare positioning. The Exact Sciences acquisition is transforming Diagnostics, with Cancer Diagnostics posting 13.8% comparable growth in Q3.

$670M in legal settlements hit Q3 GAAP results; $1.07B in legal settlements for 9M26. SG&A jumped 39.8% YoY to $4.27B, partly from Exact Sciences integration. Amortization of intangibles nearly doubled to $841M from $420M, reflecting acquisition-related cost pressure.